October 7, 2024 BERLIN, Germany — Dopavision presented its six-month clinical trial data from its MyopiaX-1 trial at the 2024 International Myopia...
May 28, 2024 BERLIN, Germany — Dopavision has announced early findings from its clinical trial for MyopiaX-1. The six-month outcomes of the...
September 26, 2023 BERLIN, Germany — Dopavision has successfully completed enrollment for its MyopiaX-1 clinical trial. MyopiaX-1 is a randomized, active-controlled trial...
June 28, 2023 BERLIN, Germany — Dopavision’s MyopiaX-1 clinical trial centers are now all active, screening and enrolling participants across Germany, Spain,...
March 21, 2023 BERLIN, Germany — Professor Dr. Jens Ellrich has been named the new Chief Scientific Officer at Dopavision, a clinical-stage...
November 17, 2022 BERLIN, Germany — Dr. Dirk Sauer has been named the Chairman of Dopavision’s Advisory Board. Dr. Sauer brings a track...
May 25, 2022 BERLIN — Dopavision has officially named a new CEO, Mark S. Wuttke, PhD. He succeeds Dopavision’s co-founder and previous...